DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/0278754 A1 Stroppolo Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2010/0278754 A1 Stroppolo Et Al US 2010O278754A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0278754 A1 Stroppolo et al. (43) Pub. Date: Nov. 4, 2010 (54) ORALLY DISINTEGRATING TABLETS WITH (86). PCT No.: PCT/EP09/S1055 SPECKLED APPEARANCE S371 (c)(1), 2), (4) Date: Jul. 6, 2010 (75) Inventors: Federico Stroppolo, Mezzovico (2), (4) (CH); Shahbaz Ardalan Related U.S. Application Data Mezzovico (CH) (60) Provisional application No. 61/026,249, filed on Feb. 5, 2008. Correspondence Address: Publication Classification ROTHWELL, FIGG, ERNST & MANBECK, PC. 51) int. C 1425 KSTREET, N.W., SUITE 800 (51) Eikyu (2006.01) WASHINGTON, DC 20005 (US) A69/20 (2006.01) (52) U.S. Cl. ....................................... 424/10.2: 424/10.3 (73) Assignee: ALPEX PHARMASA, MEZZOVICO (CH) (57) ABSTRACT Orally disintegrating tablets containing colored granules of a (21) Appl. No.: 12/811,737 water-soluble Sugar which give them a speckled appearance y x- - - 9 are described. The orally disintegrating tablets with speckled appearance are readily and easy identifiable by physicians, (22) PCT Filed: Jan. 30, 2009 nurses and patients. US 2010/0278754 A1 Nov. 4, 2010 ORALLY DISINTEGRATING TABLETS WITH Surface are easily visible, making Such tablets more identifi SPECKLED APPEARANCE able than white or monocolored tablets. 0016 Solid or semisolid forms with speckled appearance are very common among cosmetic and laundry products, such 0001. The present invention generally relates to the iden as tooth pastes or soaps. tification of orally disintegrating tablets. More particularly, 0017. They are prepared by incorporating colored beads of the invention relates to orally disintegrating tablets with a different material into the composition. speckled appearance for their easy identification by physi 0018. In case of ODT, the colored beads must be soluble cians, nurses and patients. and dissolve as fast as the tablets to avoid an unpleasant 0002 Solid pharmaceutical dosage forms for oral admin grinding sensation when the tablet disintegrates in the oral istration are usually in pill, tablet or capsule form. These cavity. Moreover, the colored beads must be stable, i.e. they dosage forms are available in a limited variety of shapes, size, must not release the color during storage, and should give and colors, and many of them are very similar to each other in minimal coloration of the oral cavity after disintegration of their outward appearance. the tablet. 0003 Frequently, users confuse such dosage forms, par 0019. The present invention relates to orally disintegrating ticularly if they are elderly or have limited vision. The con tablets containing colored granules which give a speckled sequences of taking the wrong medication can be life-threat appearance to the tablets for their readily and easy identifica ening. For this reason Health Authorities require that each dosage form and strength must be clearly identified simply by tion by physicians, nurses and patients. individual visual inspection. 0020. The orally disintegrating tablets of the invention 0004 Identification of tablets is usually made by using contains colored granules of a water-soluble Sugar. different shapes, sizes, or colors, or by color coating, printing 0021. The present invention relates to orally disintegrating or embossing them. Very often a double identification is tablets (ODT) with speckled appearance which make them required such as embossing and coloring, or coating and readily identifiable by users. printing, etc. 0022. The ODT with speckled appearance are prepared by 0005 Also correct intake of drugs is important for their mixing Soluble colored granules to the pharmaceutically effectiveness. acceptable carrier. 0006 Conventional tablets are swallowed, usually with 0023 The term “colored granules” as used herein after some water or other liquids, and the absorption of the active means granules of a color different from the color of the ingredient occurs in the gastro-intestinal tract. tablet. Colored granules are, for example, blue or yellow 0007 Orally Disintegrating Tablets (ODT) dissolve in the granules in a white tablet, blue or white granules in a yellow oral cavity by contact with saliva, do not require water for tablet, yellow or white granules in a blue tablet, dark blue ingestion and could permit a buccal absorption of the active granules in a light blue tablet, blue granules and red granules ingredient. The advantageous properties of ODT over con in a white tablet, etc. ventional tablets are making them always more and more 0024. The soluble colored granules are granular particles popular for drug administrations. of a water-soluble Sugar Such as Sucrose or a polyalcohol. 0008 For their correct intake, it would be very helpful if Specific examples of polyalcohols are Sorbitol, mannitol, ODT were more easily detectable and identifiable over con Xylitol, fructose, etc. ventional tablets. 0025 Preferably, the same polyalcohol already present in 0009. In case of ODT physical identification methods are the pharmaceutically acceptable carrier of the ODT is used limited because ODT tablets are characterized by a low hard for the preparation of the colored granules of the invention. ness which allows their rapid dissolution when in contact with (0026. Preferably, the ODT of the present invention con saliva (i.e. EU pharmacopoeia requires a disintegration time tains colored granules of mannitol. of not more than 3 minutes in water). 0027 Even if water-soluble sugars are excipients usually 0010 Coating is not usually used because it could delay present in ODT, their use to prepare colored granules suitable saliva penetration in the tablets, so delaying their disintegra for the preparation of ODT with speckled appearance tion. requires a specific particle size. 0011. As a consequence, identification of ODT by printing 0028. In fact, the particle size of the colored granules is is also unusual because this technique requires a smooth and critical. Colored granules with too small particle size are not shining tablet Surface. Such as a film- or a Sugar-coated tablet. visible and the resulting tablets have no speckled appearance. 0012 Embossing is possible but the dimension of charac On the other side, the use of colored granules with too large ters is usually too small, due to the limited tablet surface, to be particle size results in a tablet which appears uniformly col easily read by elderly people or by people with a limited ored and therefore not readily identifiable over mono-colored vision. tablets. 0013 Colored ODT can be prepared but the limited num 0029. The colored granules used in the ODT of the present ber of pharmaceutically acceptable colors make difficult to invention have a particle size from about 10um to about 1200 obtain an ODT easily identifiable over conventional colored um, preferably from about 200 um to about 800 um, most tablets. preferably from about 300 um to about 500 um. 0014. One way to solve the problem would be to make 0030. The selection of the particle size of the colored ODT identifiable by using a particular colored pattern. granules of the ODT of the present invention depends on 00.15 ODT with speckled (spotted) appearance, i.e. with a several factors. Since the sucrose or polyalcohol used for the bicolored appearance characterized by the presence of spots colored granules is preferably one of the excipients already of a different color on their surface can be easily identified by present in the ODT, the particle size must be different from users. For example, blue spots on a white or yellow tablet the particle size of the already present excipient. US 2010/0278754 A1 Nov. 4, 2010 0031. The selection of the suitable particle size also fedrine, reproterol, salmeterol, soterenol, terbutaline, depends on the desired colored pattern. For example, the use tulobuterol, and Xanoterol, C-adrenergic blockers such as of a little quantity of large particles tends to produce an ODT dapiprazole, fenspiride, nicergoline, prazosin, and yohim with few large colored spots on its surface. Higher amount of bine; B-adrenergic blockers such as acebutolol, alprenolol. Smaller particles tends to produce less discrete colored spots atenolol, befnolol, betaxolol, bupranolol, carazolol, carteolol, on the surface of the tablets. celiprolol, indenolol, levobunolol, mepindolol, metipranolol. 0032. Then, the amount of colored granules suitable for moprolol, pindolol, practolol, propranolol, and timolol; each tablet, according to the present invention, can vary adrenocortical steroid; adrenocorticotropic hormones such as within a relatively large range depending on the particle size ACTH cosintropin; alcohol deterrents such as calcium ciana of the granule. Preferably, the amount of colored granules mide citrate, and disulfiram; aldose reductase inhibitors such ranges between about 0.1% w/w and about 50% w/w, still as epalrestat, tolrestat, and Zopolrestat; aldosterone antago more preferably between about 1% w/w and about 30% w/w. nists such as canrenone, and spironolattone; anabolics Such as 0033 Preferably the colored granules useful for the ODT androisoxazole, androstenediol, methandriol, methenolon, with speckled appearance of the present invention are pre methyltrienolone, and nandrolone; narcotic analgesics Such pared by granulation of the water-soluble Sugar with an aque as alfentanil, buprenorphine, codeine and its derivatives, fen ous Suspension or solution of the coloring agent in a Suitable tanil, meperidine, methadone, morphine and its derivatives, fluid
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • SDS DATE: Apr 24, 2014
    SAFETY DATA SHEET Cat# 2570-5, -25, DUB Inhibitor, NSC-632839 SDS DATE: Apr 24, 2014 SECTION 1: PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME: DUB INHIBITOR, NSC-632839 PRODUCT CODES: Cat# 2570-5, -25 MANUFACTURER: BioVision, Inc. ADDRESS: 155 S. Milpitas Boulevard, Milpitas, CA 95035 EMERGENCY PHONE: 858-373-8066 CHEMTREC PHONE: OTHER CALLS: 408-493-1800 FAX PHONE: 408-493-1801 SECTION 2: COMPOSITION/INFORMATION ON INGREDIENTS Product Name/Chemical Name Description Volume Safety Information 2570-5: 5 mg DUB INHIBITOR, NSC-632839 Solid See below 2570-25: 25 mg SECTION 3: HAZARDS IDENTIFICATION Components CAS Number EC-No. Molecular Weight Chemical Formula DUB INHIBITOR, NSC-632839 157654-67-6 -- 339.86 C21H21NO · HCl DUB INHIBITOR, NSC-632839: Emergency Overview: OSHA Hazards: Irritant GHS Classification: Eye irritation (Category 2A) Acute aquatic toxicity (Category 2) GHS Label elements, including precautionary statements Pictogram: Signal word: Warning Hazard statement(s): H319 Causes serious eye irritation. H401 Toxic to aquatic life. Precautionary statement(s): P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. HMIS Classification Health hazard: 2 Flammability: 0 Physical hazards: 0 NFPA Rating Health Hazard: 2 Fire: 0 Reactivity Hazard: 0 Potential Health Effects Inhalation: May be harmful if inhaled. May cause respiratory tract irritation. Skin: May be harmful if absorbed through skin. May cause skin irritation. Eyes: Cause eye irritation. Ingestion: May be harmful if swallowed. SECTION 4: FIRST AID MEASURES If inhaled: If breathed in, move person into fresh air. If not breathing, give artificial respiration.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Oral Fluid Drug Test Package Insert
    Marijuana (THC) 11-nor-Δ9-THC-9 COOH 4 MTD: Methadone is a synthetic analgesic drug originally used for the Oral Fluid Drug Test treatment of narcotic addiction. In addition to use as a narcotic agonist, methadone is being used more frequently as a pain management agent. The Marijuana (THC) Δ9-THC 50 Package Insert psychological effects induced by using methadone are analgesia, sedation, and respiratory depression. Based on the saliva/plasma ratio calculated over Package insert for testing of the following drugs: > 0.02 % Alcohol (ALC) Alcohol salivary pH ranges of 6.4-7.6 for therapeutic or recreational doses of Amphetamine,Cocaine,Marijuana,Methamphetamine,Opiate,Methadone, B.A.C methadone, a cut-off <50 ng/mL is suggested. Due to this recommendation, Phencyclidine,Oxycodone,Benzodiazepine,Buprenorphine,Barbiturates, the cut-off level of the methadone test was calibrated to 30 ng/mL. Cotinine,EDDP,MDMA,6-MAM,Propoxyphene ,Fentanyl,ETG and Alcohol Tramadol(TRA) 50 Tramadol PCP: Phencyclidine is a hallucinogen and, can be detected in oral fluid as a INTENDED USE & SUMMARY result of the exchange of the drug between the circulatory system and the oral cavity.5 Fentanyl(FEN) 10 The Oral Fluid Drug And Alcohol Test is intended for screening for the Norfentanyl presence of drugs and alcohol and their metabolites in oral fluid. For professional in vitro diagnostic use only. OXY: Oxycodone is a semi-synthetic opioid with a structural similarity to Ethyl codeine. The drug is manufactured by modifying thebaine, an alkaloid found in 150 The Oral Fluid Pipette Test is a lateral flow chromatographic immunoassay for Glucuronide(ETG) the opium poppy.
    [Show full text]
  • (12) United States Patent )-X- NZ
    US008895596B2 (12) United States Patent (10) Patent No.: US 8,895,596 B2 Jiang et al. (45) Date of Patent: Nov. 25, 2014 (54) CYCLIC BENZMDAZOLE DERVATIVES (56) References Cited USEFUL AS ANT-DABETICAGENTS U.S. PATENT DOCUMENTS (75) Inventors: Jinlong Jiang, Scotch Plains, NJ (US); 5,596,025 A 1/1997 Oxman et al. Andrew J. Kassick, Scotch Plains, NJ 6,312,662 B1 11/2001 Erion et al. (US); Ahmet Kekec, Jersey City, NJ 6,489.476 B1 12/2002 Dang et al. (US); Iyassu K. Sebhat, Jersey City, NJ 7,098,220 B2 8, 2006 Rault et al. 7,268,145 B2 9, 2007 Matsumoto et al. (US) 2005, OO38068 A1 2/2005 Iyengar et al. 2005.0113283 A1 5/2005 Solow-Cordero et al. (73) Assignee: Merck Sharp & Dohme Corp, Rahway, 2005. O148643 A1 7/2005 Rui et al. NJ (US) 2005/O187277 A1 8/2005 Malti et al. 2005/0255415 A1 11/2005 Louwet et al. (*) Notice: Subject to any disclaimer, the term of this 2005/0272765 A1 12/2005 Feng et al. patent is extended or adjusted under 35 2006.0160872 A1 7/2006 Norman et al. 2006/0287356 Al 12/2006 Iyengaret al. U.S.C. 154(b) by 0 days. 2007, OO15665 A1 1/2007 Potluri et al. 2007/0O32529 A1 2/2007 Takagi et al. (21) Appl. No.: 13/578,302 2008. O1325O1 A1 6/2008 Sun et al. (22) PCT Fled: Feb. 21, 2011 FOREIGN PATENT DOCUMENTS (86) PCT NO.: PCT/US2011/025585 DE 33 16095 A1 11, 1983 EP O120403 A2 10, 1984 S371 (c)(1), EP O126030 A2 11, 1984 (2), (4) Date: Aug.
    [Show full text]
  • Review Memorandum
    510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: k062165 B. Purpose for Submission: New device C. Measurand: Barbiturates D. Type of Test: Qualitative and semi-quantitative enzyme immunoassay E. Applicant: Ortho-Clinical Diagnostics, Inc. F. Proprietary and Established Names: VITROS Chemistry Products BARB Reagent VITROS Chemistry Products Calibrator 26 VITROS Chemistry Products FS Calibrator 1 VITROS Chemistry Products DAT Performance Verifiers I, II, III, IV and V G. Regulatory Information: 1. Regulation section: 21 CFR 862.3150, Barbiturates test system 21 CFR 862.3200, Clinical Toxicology Calibrator 21 CFR 862.3180, Clinical Toxicology Control 2. Classification: Class II, (reagent, calibrator) Class I, reserved (control) 3. Product code: DIS, DLJ and DIF 4. Panel: Toxicology (91) 1 H. Intended Use: 1. Intended use(s): See Indications for use. 2. Indication(s) for use: VITROS Chemistry Products BARB Reagent: For in vitro diagnostic use only. VITROS Chemistry Products BARB Reagent is used on VITROS 5,1 FS Chemistry Systems for the semi- quantitative or qualitative determination of barbiturates (BARB) in human urine using a cutoff of 200 ng/mL or 300 ng/mL. Measurements obtained with the VITROS BARB method are used in the diagnosis and treatment of barbiturates use or overdose. The VITROS Chemistry Products BARB assay is intended for use by professional laboratory personnel. It provides only a preliminary test result. A more specific alternative chemical method must be used to confirm a result with this assay. Gas Chromatograpy/Mass Spectrometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug-of-abuse test result, particularly when evaluating a preliminary positive result.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]